Bank of Nova Scotia Decreases Stake in The Clorox Company (NYSE:CLX)

Bank of Nova Scotia trimmed its holdings in The Clorox Company (NYSE:CLXFree Report) by 56.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,782 shares of the company’s stock after selling 20,450 shares during the quarter. Bank of Nova Scotia’s holdings in Clorox were worth $2,250,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. First National Bank of Mount Dora Trust Investment Services increased its holdings in shares of Clorox by 3.2% in the 4th quarter. First National Bank of Mount Dora Trust Investment Services now owns 2,257 shares of the company’s stock valued at $322,000 after acquiring an additional 71 shares during the period. Modera Wealth Management LLC increased its stake in Clorox by 1.4% in the 3rd quarter. Modera Wealth Management LLC now owns 5,130 shares of the company’s stock valued at $672,000 after buying an additional 71 shares during the period. Czech National Bank increased its stake in Clorox by 0.3% in the 4th quarter. Czech National Bank now owns 21,718 shares of the company’s stock valued at $3,097,000 after buying an additional 71 shares during the period. Global Retirement Partners LLC increased its stake in Clorox by 7.2% in the 4th quarter. Global Retirement Partners LLC now owns 1,089 shares of the company’s stock valued at $156,000 after buying an additional 73 shares during the period. Finally, West Branch Capital LLC increased its stake in Clorox by 9.3% in the 4th quarter. West Branch Capital LLC now owns 903 shares of the company’s stock valued at $129,000 after buying an additional 77 shares during the period. 78.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Clorox from $159.00 to $158.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. DA Davidson reissued a “neutral” rating and issued a $162.00 price objective on shares of Clorox in a research note on Wednesday, April 17th. Morgan Stanley reissued an “equal weight” rating and issued a $160.00 price objective on shares of Clorox in a research note on Tuesday, March 26th. Jefferies Financial Group raised shares of Clorox from an “underperform” rating to a “hold” rating and set a $145.00 price target on the stock in a research note on Tuesday, March 26th. Finally, The Goldman Sachs Group assumed coverage on shares of Clorox in a research note on Friday, March 1st. They set a “sell” rating and a $140.00 price target on the stock. Four analysts have rated the stock with a sell rating and thirteen have given a hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $146.43.

View Our Latest Report on CLX

Clorox Price Performance

Clorox stock opened at $131.84 on Thursday. The Clorox Company has a 52 week low of $114.68 and a 52 week high of $169.14. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 9.73. The firm’s 50-day simple moving average is $140.64 and its 200 day simple moving average is $144.61. The firm has a market capitalization of $16.37 billion, a PE ratio of 68.31, a P/E/G ratio of 2.02 and a beta of 0.39.

Clorox (NYSE:CLXGet Free Report) last released its earnings results on Tuesday, April 30th. The company reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.38. The company had revenue of $1.81 billion for the quarter, compared to analyst estimates of $1.87 billion. Clorox had a net margin of 3.33% and a return on equity of 302.49%. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.51 EPS. On average, equities research analysts predict that The Clorox Company will post 5.83 EPS for the current fiscal year.

About Clorox

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Read More

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLXFree Report).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.